The global fampridine market is projected to expand at a significant rate during the forecast period. Fampridine is a drug that has been shown to improve walking speed for some adults with multiple sclerosis (MS). The drug had been approved for use by NHS Wales and NHS Scotland. The prevalence and rising cases of MS in emerging economies is the major factor that has created significant adoption of fampridine drug among population suffering from MS.  As per the National MS Society, nearly one million people are living with MS in the US, more than twice the original estimate. Apart from it, there are over 130,000 people with MS in the UK, and that nearly 7,000 people are newly diagnosed each year. MS is more than twice as common in females than males, 272 versus 106 per 100,000 population in in England. 75% of males and females with MS are aged between 40 and 74 years of age. Moreover, on average 4,950 new cases of MS are diagnosed each year in England. This rising prevalence is projected to increase the demand of fampridine in MS treatment, thereby driving the market growth. 

Besides, the inclination of market players towards new product launches and adoption of various marketing strategies in order to fulfil the growing market demands is the prominent factor helping the market to grow better. For instance, Bojian Company announced in May, 2021 that Fampridine Sustained-Release Tablets have been approved by the National Medical Products Administration, China, for the treatment of multiple sclerosis (MS) in adult patients with a walking disorder.

Segmental Outlook 

The global fampridine market is segmented based on type and form. Based on type, the market is sub-segmented into Purity: 95% and Purity: >95%. On the basis of form, the market is further sub-segmented into branded and generic. 

Global Fampridine Market Share by Form, 2021 (%) 

The Branded Segment is Projected to Hold Lucrative Market Share in Global Fampridine Market 

Based on form, the branded fampridine segment is likely to hold prominent share in the market during the forecast period. The availability of various branded drugs manufactured by major pharmaceutical companies drives the segment growth. For instance, Dalfampridine Extended-release Tablets, 10 mg, the generic pharmaceutical equivalent to Ampyra, is a branded drug developed by Hikma Pharmaceuticals USA Inc., used to support adults with multiple sclerosis improve their walking by increasing their walking pace. Apart from these, the successful clinical trials for fampridine developed by key players is aiding in segment growth. In 2019, the ENHANCE trial of fampridine reported a clinically meaningful improvement in walking ability (not just speed) in patients who had taken fampridine, compared to placebo. 

Regional Outlooks

The global fampridine market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). Among the regions, the Asia Pacific is anticipated to hold a significant share in the market followed by North America, and then Europe.

Global Fampridine Market Growth, by Region 2022-2028 

The Asia-Pacific Region Expected to Hold Considerable Growth in the Global Fampridine Market Share by region.

In Asia-Pacific, the market is steadily growing and with key players increasingly adopting strategies, the market is expected to rise over the projected horizon. In addition, the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs are the key factors that are accelerating the market growth. In aging population, the disease is more prone, hence the surge in geriatric population in the region’s major economies is further escalating the demand for fampridine in MS treatment, which in turn driving the market growth. 

Market Players Outlook

The major companies serving the global fampridine markets includes Tiefenbacher, Clearsynth, Jubilant Pharma, Teva, Kunshan Zhendong Chemical, Yancheng Huahong Chemical are some of the key players. are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding,  drug approvals, and new product launches, to stay competitive in the market. For instance,, The National Medical Products administration of China approved fampridine sustained-release tablets for the treatment of multiple sclerosis (MS) in adult patients with a walking disorder in May 2021, according to the Bojian company.

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the fampridine markets. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.